Literature DB >> 16034466

PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.

A Murati, V Gelsi-Boyer, J Adélaïde, C Perot, P Talmant, S Giraudier, L Lodé, A Letessier, B Delaval, V Brunel, M Imbert, R Garand, L Xerri, D Birnbaum, M J Mozziconacci, M Chaffanet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16034466     DOI： 10.1038/sj.leu.2403879

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  23 in total

Review 1.  Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Authors:  Jacqueline Sayyah; Peter P Sayeski
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

2.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 3.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

Review 4.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.

Authors:  Jennifer Jay; Alan Hammer; Andrea Nestor-Kalinoski; Maria Diakonova
Journal:  Mol Cell Biol       Date:  2014-10-20       Impact factor: 4.272

6.  The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.

Authors:  Dagmar Schinnerl; Klaus Fortschegger; Maximilian Kauer; João R M Marchante; Reinhard Kofler; Monique L Den Boer; Sabine Strehl
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

7.  Bigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells.

Authors:  Hao-hao Zhang; Shan Kuang; Ying Wang; Xiao-xiao Sun; Yuan Gu; Li-hong Hu; Qiang Yu
Journal:  Acta Pharmacol Sin       Date:  2015-01-26       Impact factor: 6.150

8.  Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.

Authors:  J A Kennedy; F Barabé; B J Patterson; J Bayani; J A Squire; D L Barber; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

9.  Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia.

Authors:  Kuan-Po Huang; Andrew J Chase; Nicholas C P Cross; Andrea Reiter; Tzu-Ying Li; Tso-Fu Wang; Sung-Chao Chu; Xuan-Yin Lu; Chi-Cheng Li; Ruey-Ho Kao
Journal:  Int J Hematol       Date:  2008-07-02       Impact factor: 2.490

10.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.